Newsletter
Home Biotech

Biotech

Immunotherapy Stock Acquisitions List
Biotech

Immunotherapy Stock Acquisitions List

ImmunoFrontiers Team -
0
Portfolio of Immunotherapy Stocks
Biotech

Portfolio of Immunotherapy Stocks

ImmunoFrontiers Team -
0
Lenacapavir Shows Efficacy in Treating Multidrug Resistant HIV-1 Infection
Biotech

Lenacapavir Shows Efficacy in Treating Multidrug Resistant HIV-1 Infection

ImmunoFrontiers Team -
0
Nkarta Reports First-in-Human Infusion of NKX101 for Acute Myeloid Leukemia
Biotech

Nkarta Reports First-in-Human Infusion of NKX101 for Acute Myeloid Leukemia

ImmunoFrontiers Team -
0
Jounce Presents Preclinical Data for LILRB2 Inhibitor JTX-8064
Biotech

Jounce Presents Preclinical Data for LILRB2 Inhibitor JTX-8064

ImmunoFrontiers Team -
0
BTK Inhibitor Rilzabrutinib Shows Efficacy in Immune Thrombocytopenia
Autoimmune Disease

BTK Inhibitor Rilzabrutinib Shows Efficacy in Immune Thrombocytopenia

ImmunoFrontiers Team -
0
KIT Inhibitor CDX-0159 Shows Potential As Therapy for Mast Cell Diseases
Allergy & Asthma

KIT Inhibitor CDX-0159 Shows Potential As Therapy for Mast Cell Diseases

ImmunoFrontiers Team -
0
JAK1 Inhibitor Filgotinib Shows Efficacy in Treatment of Psoriatic Arthritis
Autoimmune Disease

JAK1 Inhibitor Filgotinib Shows Efficacy in Treatment of Psoriatic Arthritis

ImmunoFrontiers Team -
0
Jounce Regains Worldwide Rights to LILRB2 Inhibitor JTX-8064 from BMS
Biotech

Jounce Regains Worldwide Rights to LILRB2 Inhibitor JTX-8064 from BMS

ImmunoFrontiers Team -
0
CAR-T Therapy Yescarta Leads to High Response Rate in Non-Hodgkin Lymphoma
Biotech

CAR-T Therapy Yescarta Leads to High Response Rate in Non-Hodgkin Lymphoma

ImmunoFrontiers Team -
0
123...6Page 1 of 6

Contact

Connect

Follow Us

ImmunoFrontiers © 2019-2021. All Rights Reserved. We are a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.

error: Content is protected.